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David J Klinke II1,2The emergence of molecular targeted therapies has
revolutionized the clinical treatment of breast cancer. To
guide treatment, patient samples are screened for expres-
sion of hormone receptors for estrogen and progesterone
and the epidermal growth factor receptor HER2. Patients
with tumors that do not express any of these three recep-
tors (that is, triple-negative breast cancer) exhibit a worse
outcome [1]. Sequencing of cancer genomes suggests that
over-expressing an oncogene or eliminating a tumor sup-
pressor gene is also associated with passenger mutations.
The presence of these passenger mutations may provide
a collective signature that distinguishes malignant from
normal cells. Conceptually, the adaptive immune system
recognizes cells that present a different antigenic signa-
ture and provides a mechanism to control for malignant
transformation. One approach to enhance anti-tumor
immunity is to increase the number of T cells, either sys-
temically, through inhibiting the action of CTLA-4, or
locally, through inhibiting the programmed cell death 1
pathway. Therapeutic inhibition of these pathways is
called immune checkpoint modulation [2]. The clinical
benefit received by a subset of patients with metastatic
melanoma demonstrates proof-of-principle for this thera-
peutic approach [3].
In a retrospective study of invasive breast cancer, we
found that increased expression of genes associated with
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unless otherwise stated.independent of molecular pathology [4]. This gene sig-
nature includes type 1 T-cell polarization and enhanced
cytotoxic T-cell and natural killer cell recruitment. While
this finding is consistent with a number of other studies
(for example, [5]), we also found that 70% of patients with
invasive triple-negative breast cancer clustered with the
cohort characterized by an increased type 1 immune sig-
nature. In examining the gene expression signature, we
found that the expression of several type 1 immunity
genes aligned along the direction of principal coordinate 1
(Figure 1A). In addition, expression of members of the
programmed cell death 1 pathway (PDCD1 and CD274)
that can be therapeutically targeted also aligned in the
same direction (Figure 1B). Other genes typically associ-
ated with local immunosuppression, including TGFB1,
MICB/MICA, HMGB1, HIF1A, FOXP3, and IL10, were
not significantly different than random noise. Collectively,
these findings suggest two points: first, patients with inva-
sive triple-negative breast cancer have an increased pro-
pensity for on-going anti-tumor immunity; and second,
therapeutic relief of the programmed cell death 1 pathway
may improve overall survival in patients with triple-
negative breast cancer.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
































Figure 1 Expression of PD-1 (PDCD1) and PD-L1 (CD274) mRNA within tumor samples correlates with a type 1 immune gene signature.
Principal coordinate analysis was applied to expression data for a subset of immune-related genes obtained from the invasive breast cancer arm
of the Cancer Genome Atlas (Figure S3 in [4]). Biplot projections of the genes along the first two principal coordinate directions, where principal
coordinate 1 corresponds to a type 1 immune signature and principal coordinate 2 corresponds to oncogenic transformation in invasive breast
cancer. Type 1 immune related genes are shown in black in (A) while immunosuppressive genes are highlighted in (B). The first two principal
coordinates capture 33% of the overall variance in the data. As principal coordinates are independent, the projection of a gene along the
corresponding axes indicates the degree to which the expression of two genes are related and the distance from the origin indicates the
strength of the covariation within the data set. The remaining principal coordinates capture progressively less variance in the data and
provide little additional information. The colored ovals radiating out from the origin indicate principal coordinate values that cannot be
distinguished from random noise, that is, a null hypothesis, with increasing levels of statistical stringency. These colored ovals were obtained by
bootstrap resampling.
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